<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01522612</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-40085-75083</org_study_id>
    <secondary_id>2011-002947-83</secondary_id>
    <nct_id>NCT01522612</nct_id>
  </id_info>
  <brief_title>Colorectal Cancer (CRC) Cetuximab Elderly Frail</brief_title>
  <official_title>Treatment of Patients With KRAS Wild Type Advanced Colorectal Cancer (CRC) With 5-Fluorouracil (5-FU) or 5- FU Plus an Epidermal Growth Factor Receptor (EGFR) Inhibitor (Cetuximab) Based on a Comprehensive Geriatric Assessment (CGA).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVE: The principal objective of the trial is to evaluate whether the addition of&#xD;
      cetuximab associated with 5-fluorouracil in elderly patients with KRAS wild type advanced&#xD;
      colorectal cancer (CRC) prolongs Progression Free Survival, compared with 5-fluorouracil&#xD;
      alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary efficacy analyses will be performed on the Intention-to-treat population.&#xD;
&#xD;
      The safety analyses will be performed on the Safety population.&#xD;
&#xD;
        -  Median PFS and OS in each treatment arm with its 95% CI, estimated by the Kaplan-Meier&#xD;
           technique&#xD;
&#xD;
        -  Response rates by treatment arm with their exact 95% CI&#xD;
&#xD;
        -  IADL sum score, G8 sum score and social situation by treatment arm at baseline and at&#xD;
           each timepoint of assessment&#xD;
&#xD;
        -  QoL scores from the EORTC QLQ-C30 and QLQ-ELD14 modules by treatment arm at baseline and&#xD;
           at each timepoint of assessment&#xD;
&#xD;
        -  Safety data by treatment arm in the Safety population. Worst toxicity grade over all&#xD;
           cycles according to the CTCAE criteria version 4.0 by treatment arm.&#xD;
&#xD;
        -  Pharmaco-economics evaluation&#xD;
&#xD;
      Summary of proposed Phase II trial characteristics:&#xD;
&#xD;
        1. Total number of randomized patients: 150.&#xD;
&#xD;
        2. Total number of events at phase II analysis for primary endpoint: 110.&#xD;
&#xD;
        3. Total number of patients screened over the phase II: 250.&#xD;
&#xD;
        4. Total number of patients treated with cetuximab for the Phase II study: 75.&#xD;
&#xD;
        5. Maximum study duration: 19 months.&#xD;
&#xD;
      In the present study, HRQoL is an important secondary endpoint. The objective of the HRQoL&#xD;
      data collection in this Phase II trial is to assess the impact of the addition of cetuximab&#xD;
      on patients' HRQoL during treatment.&#xD;
&#xD;
      The hypothesis is that there will be no difference in patients' HRQoL between both treatment&#xD;
      arms during treatment. The HRQoL domains (from the EORTC QLQ-C30 module) which are expected&#xD;
      to be affected by treatment (to the same extent in both arms) are Global health status,&#xD;
      Fatigue, Pain and Stool habits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor accrual&#xD;
  </why_stopped>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>19 months from first patient in</time_frame>
    <description>Progression will be defined according to the &quot;RECIST V1.1&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>19 months from first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>19 months from first patient in</time_frame>
    <description>according to the RECIST V1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Instrumental Activities of Daily Living (IADL) score</measure>
    <time_frame>19 months from first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in G8 geriatric assessment screening tool</measure>
    <time_frame>19 months from first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in social situation</measure>
    <time_frame>19 months from first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of Quality of Life (EORTC-QLQ C30 and QLQ-ELD14)</measure>
    <time_frame>14 days before randomization; 6 weeks, 14 weeks, 22 weeks and 38 weeks after randomization; 30 days after last treatment administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>19 months from first patient in</time_frame>
    <description>Adverse events will be graded according to the &quot;Common Terminology Criteria for Adverse events&quot; CTCAE,version 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Economy assessments</measure>
    <time_frame>19 months from first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of elderly minimal dataset comprehensive geriatric assessment (EMDCGA), as evaluated by G8 instrument</measure>
    <time_frame>14 days before randomization; 6 weeks, 14 weeks, 22 weeks and 38 weeks after randomization; 30 days after last treatment administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of elderly minimal dataset comprehensive geriatric assessment (EMDCGA), as evaluated by Instrumental Activities of Daily Life (IADL) questionnaire</measure>
    <time_frame>14 days before randomization; 6 weeks, 14 weeks, 22 weeks and 38 weeks after randomization; 30 days after last treatment administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of elderly minimal dataset comprehensive geriatric assessment (EMDCGA), as evaluated by social situation questionnaire</measure>
    <time_frame>14 days before randomization; 6 weeks, 14 weeks, 22 weeks and 38 weeks after randomization; 30 days after last treatment administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>5-fluorouracil/leucovorin plus cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5-fluorouracil/leucovorin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>500 mg/m2 on day 1, Every 14 days Intravenously</description>
    <arm_group_label>5-fluorouracil/leucovorin plus cetuximab</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>Every 2 weeks, 400 mg/m2 on day 1; 2400 mg/m2 from day 1 to day 3, intravenously</description>
    <arm_group_label>5-fluorouracil/leucovorin alone</arm_group_label>
    <arm_group_label>5-fluorouracil/leucovorin plus cetuximab</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin</intervention_name>
    <description>Every 2 weeks, Racemic leucovorin 200 mg/m2 or l-leucovorin 100 mg/m2 on day 1, intravenously</description>
    <arm_group_label>5-fluorouracil/leucovorin alone</arm_group_label>
    <arm_group_label>5-fluorouracil/leucovorin plus cetuximab</arm_group_label>
    <other_name>Folinic Acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed metastatic colorectal cancer&#xD;
&#xD;
          -  Measurable disease according to RECIST V1.1&#xD;
&#xD;
          -  Histological local review and analysis of KRAS&#xD;
&#xD;
          -  Age ≥ 80 or ≥ 70 in combination with functional restrictions defined as limitation in&#xD;
             at least 2 of 8 IADL&#xD;
&#xD;
          -  WHO performance status 0, 1 or 2&#xD;
&#xD;
          -  Adequate bone marrow reserves, hepatic function &amp; renal function&#xD;
&#xD;
          -  Normal 12 lead ECG without clinically significant abnormalities&#xD;
&#xD;
          -  Written informed consent before randomization according to ICH/EU GCP, and local,&#xD;
             national and international regulations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior systemic chemotherapy for metastatic disease&#xD;
&#xD;
          -  Previous exposure to EGFR or VEGF/VEGFR targeted therapy&#xD;
&#xD;
          -  Patients may have received chemotherapy in the adjuvant or neoadjuvant setting (CRC).&#xD;
             The treatment-free interval should be 6 months or more from the end of (neo-)adjuvant&#xD;
             therapy&#xD;
&#xD;
          -  Previous radiotherapy, either in the adjuvant setting or for the treatment of bone&#xD;
             metastases, is allowed provided that the measurable lesions are outside the radiation&#xD;
             fields&#xD;
&#xD;
          -  Persistence of clinically relevant treatment-related toxicities from previous&#xD;
             chemotherapy and/or radiotherapy (adjuvant or neo-adjuvant setting)&#xD;
&#xD;
          -  Treatment with other investigational drugs or treatment in another clinical trial&#xD;
             within the past four weeks before start of treatment or concomitantly with this trial&#xD;
&#xD;
          -  Known alcohol or drug abuse&#xD;
&#xD;
          -  Clinically significant cardiovascular disease&#xD;
&#xD;
          -  Evidence of uncontrolled medical comorbidities despite adequate treatment&#xD;
&#xD;
          -  Patients who have suffered a cerebrovascular accident or transient ischemic attack&#xD;
             within the past 12 months&#xD;
&#xD;
          -  History, within the past 5 years, of malignancies other than CRC&#xD;
&#xD;
          -  Psychological, familial, sociological, or geographical condition potentially hampering&#xD;
             compliance with the study protocol and followup schedule&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Peeters, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>UNIVERSITAIR ZIEKENHUIS ANTWERPEN, Edegem, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrich Wedding, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UNIVERSITAETSKLINIKUM JENA, Jena, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AZ Turnhout - Campus Sint Elisabeth</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bank Of Cyprus Oncology Centre</name>
      <address>
        <city>Nicosia</city>
        <country>Cyprus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Cyprus</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <link>
    <url>http://www.eortc.be/clinicaltrials/details.asp?protocol=40085</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>January 27, 2012</study_first_submitted>
  <study_first_submitted_qc>January 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2012</study_first_posted>
  <last_update_submitted>June 9, 2016</last_update_submitted>
  <last_update_submitted_qc>June 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>KRAS Wild Type</keyword>
  <keyword>Frail Elderly</keyword>
  <keyword>QLQ-C30</keyword>
  <keyword>QLQ-ELD14</keyword>
  <keyword>CGA</keyword>
  <keyword>EGFR</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>5-FU</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

